AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Flurandrenolide works by suppressing the immune response and reducing inflammation in the skin. It inhibits the production of inflammatory mediators, such as prostaglandins and leukotrienes, which play a role in the inflammatory process. By decreasing inflammation, flurandrenolide can alleviate symptoms such as redness, swelling, and discomfort.
Itching Relief: Flurandrenolide helps relieve itching (pruritus) associated with skin conditions such as eczema (atopic dermatitis), psoriasis, allergic reactions, and dermatitis. It acts by reducing inflammation and suppressing the release of histamine and other itch-inducing substances in the skin, providing relief from itching and discomfort.
Skin Disorders: Flurandrenolide is indicated for the treatment of various skin disorders, including eczema, psoriasis, allergic dermatitis, contact dermatitis, seborrheic dermatitis, and other inflammatory or allergic skin conditions. It is available in different formulations, including creams, ointments, lotions, and tapes, for topical application to affected areas of the skin.
Dosage and Duration: The dosage and duration of treatment with flurandrenolide depend on the severity of the skin condition being treated, as well as individual patient factors such as age, skin type, and response to therapy. It is typically applied thinly and evenly to the affected area of the skin once or twice daily, as directed by a healthcare professional. Treatment duration may vary from a few days to several weeks, but prolonged use should be avoided to minimize the risk of adverse effects.
Side Effects: Like other corticosteroids, flurandrenolide may cause side effects, particularly with prolonged or excessive use. Common side effects may include skin irritation, burning, stinging, itching, dryness, or redness at the site of application. In rare cases, systemic absorption of flurandrenolide may occur, leading to potential systemic side effects such as adrenal suppression, Cushing's syndrome, hyperglycemia (high blood sugar), glaucoma, cataracts, and skin thinning. Patients should be advised to use flurandrenolide sparingly and according to the prescribed regimen to minimize the risk of side effects.
Precautions: Flurandrenolide should be used with caution in certain populations, including children, elderly individuals, pregnant or breastfeeding women, and patients with preexisting medical conditions such as diabetes, hypertension, or immune suppression. It should not be applied to broken or infected skin, and contact with the eyes, mouth, or mucous membranes should be avoided. Patients should be instructed to wash their hands thoroughly after applying flurandrenolide and to avoid occlusive dressings unless directed by a healthcare provider.
Drug Interactions: Flurandrenolide may interact with other medications, particularly other corticosteroids or immunosuppressants, increasing the risk of systemic side effects or reducing the effectiveness of treatment. Patients should inform their healthcare providers about all prescription drugs, over-the-counter medications, vitamins, and herbal supplements they are taking before starting flurandrenolide therapy to minimize the risk of drug interactions and potential complications.
Monitoring and Follow-up: Patients receiving flurandrenolide therapy should undergo regular monitoring of their skin condition and treatment response, as well as assessment for any signs of systemic side effects. Close collaboration between the patient and healthcare provider is essential to ensure the safe and effective use of flurandrenolide and to address any concerns or adverse reactions that may arise during treatment.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Roseburia | genus | Decreases | 👪 Source Study | |
Mediterraneibacter | genus | Decreases | 👪 Source Study | |
Segatella | genus | Decreases | 👪 Source Study | |
Roseburia intestinalis | species | Decreases | 📓 Source Study | |
[Ruminococcus] torques | species | Decreases | 📓 Source Study | |
Segatella copri | species | Decreases | 📓 Source Study | Over 70%ile Indicator of mycotoxin present |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.5 | 0.5 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergies | 0 | 0 | |
Alzheimer's disease | 1.1 | -1.1 | |
Ankylosing spondylitis | 0 | 0 | |
Anorexia Nervosa | 0.5 | -0.5 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Asthma | 0.5 | 0.5 | 0 |
Atherosclerosis | 0.8 | -0.8 | |
Atrial fibrillation | 0 | 0 | |
Autism | 0.8 | 0.6 | 0.33 |
Autoimmune Disease | 0.5 | -0.5 | |
Bipolar Disorder | 0.5 | -0.5 | |
Brain Trauma | 0.5 | -0.5 | |
Celiac Disease | 0.3 | 0.3 | |
Cerebral Palsy | 0.5 | -0.5 | |
Chronic Kidney Disease | 0.2 | 0.8 | -3 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
Chronic Urticaria (Hives) | 0 | 0 | |
Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
Cognitive Function | 0.5 | -0.5 | |
Colorectal Cancer | 0.8 | 0.5 | 0.6 |
Constipation | 0.5 | -0.5 | |
Coronary artery disease | 0.5 | -0.5 | |
COVID-19 | 0.9 | -0.9 | |
Crohn's Disease | 0.5 | 0.5 | 0 |
cystic fibrosis | 0.5 | -0.5 | |
deep vein thrombosis | 0.5 | -0.5 | |
Depression | 0.5 | 0.8 | -0.6 |
Endometriosis | 0.5 | -0.5 | |
Fibromyalgia | 0.5 | 0 | 0 |
Functional constipation / chronic idiopathic constipation | 0.3 | 0.8 | -1.67 |
gallstone disease (gsd) | 0.5 | -0.5 | |
Graves' disease | 0.5 | -0.5 | |
Hashimoto's thyroiditis | 0.8 | 0.2 | 3 |
Heart Failure | 0.5 | -0.5 | |
High Histamine/low DAO | 0.5 | 0.5 | |
hypertension (High Blood Pressure | 0.2 | 0.5 | -1.5 |
IgA nephropathy (IgAN) | 0.6 | -0.6 | |
Inflammatory Bowel Disease | 0.9 | -0.9 | |
Insomnia | 0.5 | -0.5 | |
Intelligence | 0 | 0 | |
Irritable Bowel Syndrome | 0.8 | 0.5 | 0.6 |
ischemic stroke | 0.5 | -0.5 | |
Liver Cirrhosis | 0.5 | 0.5 | 0 |
Long COVID | 0.5 | -0.5 | |
Low bone mineral density | 0.5 | -0.5 | |
Menopause | 0.5 | -0.5 | |
Metabolic Syndrome | 0.5 | 0.5 | 0 |
Mood Disorders | 0.5 | 0.5 | 0 |
Multiple Sclerosis | 0.6 | -0.6 | |
myasthenia gravis | 0.5 | -0.5 | |
neuropathic pain | 0.5 | -0.5 | |
Neuropathy (all types) | 0.5 | -0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.5 | 0.2 |
Obesity | 0.8 | 0.5 | 0.6 |
obsessive-compulsive disorder | 0.3 | -0.3 | |
Osteoporosis | 0.5 | 0.5 | |
Parkinson's Disease | 0.8 | 0.9 | -0.13 |
Polycystic ovary syndrome | 0.5 | 0.5 | 0 |
Psoriasis | 0.6 | -0.6 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.5 | 0.2 |
Rosacea | 0.2 | 0.5 | -1.5 |
Schizophrenia | 0.5 | -0.5 | |
Sjögren syndrome | 0 | 0 | |
Sleep Apnea | 0.5 | -0.5 | |
Stress / posttraumatic stress disorder | 0.5 | 0.5 | 0 |
Systemic Lupus Erythematosus | 0.5 | -0.5 | |
Tic Disorder | 0 | 0 | |
Type 1 Diabetes | 0.5 | -0.5 | |
Type 2 Diabetes | 0.5 | 0.5 | 0 |
Ulcerative colitis | 0.6 | -0.6 | |
Unhealthy Ageing | 0.2 | 0.5 | -1.5 |